FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Inc., a biopharmaceutical company, announced that it has settled $637,650 in debt with unrelated creditors through the issuance of 545,000 Class B shares at a price of $1 $.17 per share. Furthermore, the company also allocated 55,000 restricted stock units (RSUs) to various consultants, in accordance with the company's equity incentive plan. These RSUs will allow holders to acquire one class B share of the company upon fulfillment of the acquisition conditions.

This initiative is part of FSD Pharma's ongoing efforts to consolidate its portfolio of innovative assets in the biotechnology solutions sector, focusing in particular on the treatment of neurodegenerative and metabolic disorders as well as disorders related to alcohol consumption. FSD also places emphasis on development and research through Lucid Psycheceuticals, its wholly owned subsidiary, particularly around Lucid-MS, a new patented chemical entity. Finally, FSD Pharma continues to develop innovative formulations for alcohol use disorders through strategic investments by its wholly owned subsidiary, FSD Strategic Investments Inc.